# Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

> **NCT01290341** · PHASE3 · COMPLETED · sponsor: **Merz North America, Inc.** · enrollment: 860 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** NAFT-600 (naftin 2 % gel)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01290341
- **Lead sponsor:** Merz North America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 860 (ACTUAL)
- **Last updated:** 2013-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01290341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01290341, "Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01290341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*